Czechia· CZ-0241065
MIDAZOLAM ACCORD
A midazolam product, registered in Czechia by ACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava. The same ATC class is registered in 14 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Midazolam is registered in 14 of 19 countries.
Countries holding a registration under ATC N05CD08 (midazolam), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 9 of them publish a price we can compare per daily dose
Midazolam · ATC N05CD08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of midazolam costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.55 in Switzerland to $4.74 in Finland — a ×8.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Midazolam · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- FI Finland$4.74
- CH Switzerland$0.55
The record
At a glance
SÚKL (Czech Republic)- Manufacturer
- ACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- Country
- Czechia (CZ)
- ATC code
- N05CD08
- ATC class
- Midazolam
- Defined daily dose
- 5 mg, N
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- August 24, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02410651X5MLCZK 304.64
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
316 interactions on record for midazolam.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Midazolam · interactions on record
316 records
- 9 severe
- 156 moderate
- 34 minor
- 57 info
Most severe, free to view
- KetoconazoleH02CA03severe
- KetoconazoleJ02AB02severe
- FluconazoleJ02AC01severe
- Darunavir and cobicistatJ05AR14severe
60 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N05CD08
Midazolam, as other registers publish it.
- IcelandBuccolamNeuraxpharm Pharmaceuticals S.L.
- IcelandBuccolamNeuraxpharm Pharmaceuticals S.L.
- PolandBuccolamNeuraxpharm Pharmaceuticals, S.L.
- IcelandBuccolamNeuraxpharm Pharmaceuticals S.L.
- PolandBuccolamNeuraxpharm Pharmaceuticals, S.L.
- NorwayBuccolamNeuraxpharm Pharmaceuticals S.L.
- DenmarkBuccolamNeuraxpharm Pharmaceuticals S.L.
- IcelandBuccolamNeuraxpharm Pharmaceuticals S.L.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf121b6b-ce2f-4121-ad92-a221ca507b22 GET /v1/drugs/cf121b6b-ce2f-4121-ad92-a221ca507b22?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ/INF SOL ISP",
"source": "sukl",
"strength": "1MG/ML",
"pack_size": "1X5ML",
"substance": "5534",
"cz_kod_sukl": "0241065",
"product_type": "CH",
"registration_state": "R",
"registration_number": "57/145/19-C"
}See everything about midazolam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.